Phacilitate Leaders Forum

17th - 18th SEPTEMBER 2019

ROYAL LANCASTER LONDON

Patient Access and the Delivery of Advanced Therapies - Part One

Patient Access and the Delivery of Advanced Therapies - Part One

An interview with Jacqueline Barry, Chief Clinical Officer at Cell and Gene Therapy Catapult

Healthcare infrastructure and the patient journey are increasingly important factors for our industry. The delivery of advanced therapy treatments requires highly specialised skillsets and technology that cannot be found in all, indeed many, healthcare settings.

The UK is leading the way, forming a network of advanced therapies treatment centres; joint ventures set up to include industry, academic and NHS partners and funded by Innovate UK. Cell and Gene Therapy Catapult are supporting the development of this network and we spoke to Dr Jacqueline Barry, the Chief Clinical Officer at the CGT Catapult about the future of patient access to therapies and how industry sectors will work together to improve delivery.

Watch the video to find out the answers to these questions…

  1. Are specific centres of excellence the answer to patient access?
  2. What knowledge can clinics and industry share to expedite advanced therapies into mainstream healthcare?
  3. How should centres of excellence align their GMP requirements to match manufacturers?
  4. What role do treatment centres and their clinicians have in educating patients?
Part two of 'Patient Access and Delivery of Advanced Therapies' with Dr Matthew Frigault is coming soon,  subscribe to the Phacilitate:Exchange fortnightly newsletter to get it delivered straight to your inbox.
Testimonials
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Jean-Philippe Combal
    GenSight Biologics
  • The conference consistently proves to be a great forum for networking with industry leaders in the development of cellular and gene therapies as well as vendors for important technologies and services.
    Michael Covington
    Juno Therapeutics, Inc
  • It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance
    Bertrand Alexandre
    Celyad
  • Phacilitate EU delivered it's promise and more, the topics discussed were highly relevant, with very good and professional speakers and panelists. You will see me next year in Berlin.
    Dr Ohad Karnieli
    Karnieli Ltd